Navigation Links
Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Date:9/2/2009

SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company's lead product candidate, picoplatin, at three upcoming investor conferences:

  • Baird Healthcare Conference
    • Wednesday, September 9, 2009 at 1:15 p.m. Eastern Time
    • Four Seasons Hotel in New York City

  • Rodman & Renshaw 11th Annual Healthcare Conference
    • Thursday, September 10, 2009 at 10:25 a.m. Eastern Time
    • The Palace Hotel in New York City

  • NewsMakers in the Biotech Industry Conference
    • Wednesday, September 16, 2009 at 11:30 a.m. Eastern Time
    • Millennium Broadway Hotel in New York City

Live audio web casts of Poniard's presentations will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
3. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
4. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
5. Poniard Pharmaceuticals Files Shelf Registration
6. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
7. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
8. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
(Date:3/22/2017)... ... ... executive recruitment firm, Slone Partners, is proud to have been named a Top 50 ... Scanlon Media is one of the most respected life science publications in the United ... , “It is a great honor for Slone Partners to be part of this ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... has unveiled its innovative Quantum peristaltic pump with patented ReNu single-use (SU) ... the new standard for high-pressure feed pumps in SU tangential flow filtration ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
Breaking Biology News(10 mins):